|
Journal Papers,
Abstracts and Commentaries
|
| |
|
Effect of Vicriviroc With or Without Ritonavir on Oral Contraceptive
Pharmacokinetics:
A Randomized, Open-Label, Parallel-Group, Fixed-Sequence Crossover Trial in
Healthy Women.
Kasserra C, Li J, March B, O'Mara E.
Clin
Ther. 2011 Oct 18.
Abstract
FULL-TEXT ARTICLE
Identification and Characterization of INCB9471, an Allosteric Non-Competitive
Small Molecule Antagonist of
CCR5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1
Infection.
Shin N, Solomon K, Zhou N, Wang KH, et al
J Pharmacol Exp Ther.
2011 Apr 1
Paper
'A WEEK-IN-REVIEW
FEATURED REPORT
Pharmacokinetic interaction of vicriviroc with other antiretroviral agents:
results from
a series of fixed-sequence and parallel-group clinical trials.
Kasserra C, O'Mara E
Clin Pharmacokinet. 2011 Apr 1;50(4):267-80.
Abstract
Pharmacokinetic interaction of vicriviroc with other antiretroviral
agents: results from a series
of fixed-sequence and parallel-group clinical trials.
Kasserra C, O'Mara E.
Clin Pharmacokinet.
2011 Apr 1;50(4):267-80.
Abstract
Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1
Isolated from
Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1).
McNicholas PM, Mann PA, Lee E, et al
J Acquir Immune Defic Syndr. 2011 Mar
1;56(3):222-9.
Abstract
|
Vicriviroc, a new CC-chemokine receptor 5 inhibitor for
treatment of HIV: properties, promises and challenges.
Lenz JC, Rockstroh JK.
Expert Opin Drug Metab Toxicol.
2010 Sep;6(9):1139-50
Abstract
|
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5
antagonists depends on both N-terminal
and extracellular loop domains of drug-bound CCR5.
Tilton JC, Wilen CB, Didigu CA, et
a,l
J Virol. 2010
Oct;84(20):10863-76.
Abstract
|
Three-year safety and efficacy of vicriviroc, a CCR5
antagonist, in HIV-1-infected treatment-experienced patients.
Wilkin TJ, Su Z, Krambrink A, Long J,
et al
J Acquir Immune Defic Syndr.
2010 Aug 15;54(5):470-6.
Abstract |
Effect of vicriviroc on the QT/corrected QT interval and
central nervous system in healthy subjects.
O'Mara E, Kasserra C, Huddlestone JR, et al
Antimicrob Agents Chemother.
2010 Jun;54(6):2448-54
Abstract |
Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a
ritonavir-containing
regimen.
Kasserra C, Sansone-Parsons A, Keung A,.
et al
Clin Pharmacokinet. 2010
Jun;49(6):397-406.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Characterization of Emergent HIV Resistance in Treatment-Naive Subjects
Enrolled in a Vicriviroc Phase 2 Trial
McNicholas P, Wei Y, Whitcomb J, et al
J Infect Dis. 2010 Apr 7
Abstract |
The Effect of Vicriviroc on the QT/QTc Interval and Central Nervous
System in
Healthy Subjects.
O'Mara E, Kasserra C, Huddlestone JR, .et al
Antimicrob Agents Chemother. 2010 Mar 29
Abstract
|
A WEEK-IN-REVIEW
FEATURED REPORT
Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the
CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects
(ACTG Protocol 5211).
Crawford KW, Li C, Keung A, Su Z, et al
J Acquir Immune Defic
Syndr. 2010 Jan 12
Abstract |
A WEEK-IN REVIEW FESTERED REPORT
Vicriviroc in Combination Therapy with an Optimized Regimen for
Treatment-Experienced
Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial.
Suleiman J, Zingman BS, Diaz RS, et al
J Infect Dis. 2010 Jan 11
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Vicriviroc: a CCR5 antagonist for treatment-experienced
patients with HIV-1 infection.
Kümmerle T, Lehmann C, Hartmann P,
et al
Expert Opin Investig Drugs.
2009 Nov;18(11):1773-85
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Response to Vicriviroc in Treatment-Experienced Subjects, as
Determined by an Enhanced-Sensitivity
Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group
A5211.
Su Z, Gulick RM, Krambrink A, et al
J Infect Dis. 2009 Oct 29.
Abstract |
Short-Term Administration of the CCR5 Antagonist Vicriviroc to
Patients With HIV
and HCV Coinfection is Safe and Tolerable.
Fätkenheuer G, Hoffmann C, Slim J,
et al
J Acquir Immune Defic Syndr.
2009 Oct 15
Abstract |
Vicriviroc, a CCR5 receptor antagonist for the potential treatment of
HIV infection.
Klibanov OM
Curr Opin Investig Drugs.
2009 Aug;10(8):845-59.
Abstract |
Inefficient entry of vicriviroc-resistant HIV-1 via the
inhibitor-CCR5 complex at low cell surface CCR5 densities.
Pugach P, Ray N, Klasse PJ, et al
Virology.
2009 Mar 19.
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5
Inhibitor, in HIV-1-Infected,
Treatment-Experienced Patients: AIDS Clinical Trials Group 5211.
Gulick RM, Su Z, Flexner C, et al
J Infect Dis. 2007 Jul
15;196(2):304-312.
Abstract |
|
|
|
|
|
|
| |
Antiviral activity, pharmacokinetics and safety of vicriviroc,
an oral CCR5 antagonist, during
14-day monotherapy in HIV-infected adults.
Schürmann D, Fätkenheuer G, Reynes J, et al
AIDS. 2007 Jun;21(10):1293-1299.
Abstract |
|
|
|
|
|
|
| |
Access denied? The status of co-receptor inhibition to counter HIV
entry.
Biswas P, Tambussi G, Lazzarin A.
Expert Opin Pharmacother. 2007 May;8(7):923-33.
Abstract
|
|
|
|
| |
HIV type 1 chemokine coreceptor use among antiretroviral-experienced
patients screened for a
clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ, Su Z, Kuritzkes DR, et al
Clin Infect Dis. 2007 Feb 15;44(4):591-5.
Abstract
|
|
|
| |
Potent antiviral synergy between monoclonal antibody and
small-molecule CCR5 inhibitors of
human immunodeficiency virus type 1.
Murga JD, Franti M, Pevear DC,et al
Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96
Abstract
|
|
|
| |
FULL TEXT
ARTICLE
Discovery and characterization of vicriviroc (SCH 417690), a CCR5
antagonist with potent
activity against human immunodeficiency virus type 1.
Strizki JM, Tremblay C, Xu S, et al
Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9
Abstract |
|
|
|
|
New
and Noteworthy
ARV
Investigational Drugs Main Page
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader